🔎 Trials Near Me

Utama › Leukemia Mieloid Fase Kronik › New York

Kajian klinikal Leukemia Mieloid Fase Kronik di New York

5 kajian untuk Leukemia Mieloid Fase Kronik sedang mencari peserta di lokasi di New York.

Bandar di New York

Teks kajian rasmi (Bahasa Inggeris)

Study of Olverembatinib (HQP1351) in Patients With CML-CP

  • Ascentage Investigative Site #1068, Rochester
  • Ascentage Investigative Site #1053, Shirley
  • Ascentage Investigative Site #1160, Stony Brook
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06423911

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04838041

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

  • NY Cancer and Blood Specialists, East Setauket
  • SUNY Upstate Medical University, Syracuse
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 100 · Semua jantina · Dikemas kini 20 Jul 2026 · NCT07091019

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

  • Memorial Sloan Kettering Cancer Center, New York
  • Montefiore Medical Center, The Bronx
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Apr 2026 · NCT05304377

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

  • Memorial Sloan Kettering Cancer Center - Main Campus, New York
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jan 2026 · NCT06163430

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.